{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:42:13Z","timestamp":1782798133007,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006378","name":"Purdue University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006378","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.ejmech.2018.06.023","type":"journal-article","created":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T01:32:27Z","timestamp":1529026347000},"page":"797-805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["N-(1,3,4-oxadiazol-2-yl)benzamide analogs, bacteriostatic agents against methicillin- and vancomycin-resistant bacteria"],"prefix":"10.1016","volume":"155","author":[{"given":"Clement","family":"Opoku-Temeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Naclerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1555-7963","authenticated-orcid":false,"given":"Haroon","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neetu","family":"Dayal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader S.","family":"Abutaleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed N.","family":"Seleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2280-9359","authenticated-orcid":false,"given":"Herman O.","family":"Sintim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejmech.2018.06.023_bib1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4161\/viru.22507","article-title":"New antibiotic agents in the pipeline and how they can help overcome microbial resistance","volume":"4","author":"Gould","year":"2013","journal-title":"Virulence"},{"issue":"3","key":"10.1016\/j.ejmech.2018.06.023_bib2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1139\/cjm-2014-0063","article-title":"Something old, something new: revisiting natural products in antibiotic drug discovery","volume":"60","author":"Wright","year":"2014","journal-title":"Can. J. Microbiol."},{"issue":"4","key":"10.1016\/j.ejmech.2018.06.023_bib3","first-page":"277","article-title":"The antibiotic resistance crisis: part 1: causes and threats","volume":"40","author":"Ventola","year":"2015","journal-title":"P.\u00a0T."},{"issue":"12","key":"10.1016\/j.ejmech.2018.06.023_bib4","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/nrmicro2693","article-title":"Tackling antibiotic resistance","volume":"9","author":"Bush","year":"2011","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2018.06.023_bib5","series-title":"Antibiotic Resistance Threats in the United States, 2013","first-page":"114","author":"Frieden","year":"2013"},{"issue":"11","key":"10.1016\/j.ejmech.2018.06.023_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002184","article-title":"Will 10 million people die a year due to antimicrobial resistance by 2050?","volume":"13","author":"de Kraker","year":"2016","journal-title":"PLoS Med."},{"issue":"4","key":"10.1016\/j.ejmech.2018.06.023_bib7","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1086\/520437","article-title":"Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors","volume":"29","author":"Gorak","year":"1999","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.ejmech.2018.06.023_bib8","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3201\/eid1605.090851","article-title":"Methicillin-Resistant Staphylococcus aureus carriage and risk factors for skin infections, Southwestern Alaska, USA","volume":"16","author":"Stevens","year":"2010","journal-title":"Emerg. Infect. Dis."},{"issue":"11","key":"10.1016\/j.ejmech.2018.06.023_bib9","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3201\/eid1411.080381","article-title":"Molecular epidemiology of methicillin-resistant Staphylococcus aureus, rural southwestern Alaska","volume":"14","author":"David","year":"2008","journal-title":"Emerg. Infect. Dis."},{"issue":"8","key":"10.1016\/j.ejmech.2018.06.023_bib10","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3201\/eid1308.061575","article-title":"Skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus USA300 clone","volume":"13","author":"Johnson","year":"2007","journal-title":"Emerg. Infect. Dis."},{"issue":"4","key":"10.1016\/j.ejmech.2018.06.023_bib11","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3201\/eid1704.100482","article-title":"High rates of Staphylococcus aureus USA400 infection, Northern Canada","volume":"17","author":"Golding","year":"2011","journal-title":"Emerg. Infect. Dis."},{"issue":"15","key":"10.1016\/j.ejmech.2018.06.023_bib12","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1001\/jama.298.15.1763","article-title":"Invasive methicillin-resistant Staphylococcus aureus infections in the United States","volume":"298","author":"Klevens","year":"2007","journal-title":"J.\u00a0Am. Med. Assoc."},{"issue":"2","key":"10.1016\/j.ejmech.2018.06.023_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1592\/phco.27.2.227","article-title":"Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections","volume":"27","author":"Drew","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"8","key":"10.1016\/j.ejmech.2018.06.023_bib14","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJM199808203390806","article-title":"Staphylococcus aureus infections","volume":"339","author":"Lowy","year":"1998","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"Suppl 2","key":"10.1016\/j.ejmech.2018.06.023_bib15","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1111\/j.1444-0903.2005.00976.x","article-title":"Antibiotics currently used in the treatment of infections caused by Staphylococcus aureus","volume":"35","author":"Rayner","year":"2005","journal-title":"Intern. Med. J."},{"issue":"5","key":"10.1016\/j.ejmech.2018.06.023_bib16","doi-asserted-by":"crossref","first-page":"704","DOI":"10.4103\/0971-5916.91001","article-title":"Vancomycin resistance among methicillin-resistant Staphylococcus aureus isolates from intensive care units of tertiary care hospitals in Hyderabad","volume":"134","author":"Thati","year":"2011","journal-title":"Indian J. Med. Res."},{"issue":"3","key":"10.1016\/j.ejmech.2018.06.023_bib17","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1128\/AAC.45.3.883-892.2001","article-title":"Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in\u00a0vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin","volume":"45","author":"Gilbert","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.ejmech.2018.06.023_bib18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1021\/id500052s","article-title":"Solving the antibiotic crisis","volume":"1","author":"Wright","year":"2015","journal-title":"ACS Infect. Dis."},{"issue":"11","key":"10.1016\/j.ejmech.2018.06.023_bib19","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.tim.2016.06.009","article-title":"Antibiotic adjuvants: rescuing antibiotics from resistance","volume":"24","author":"Wright","year":"2016","journal-title":"Trends Microbiol."},{"issue":"5","key":"10.1016\/j.ejmech.2018.06.023_bib20","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.bbamem.2015.10.018","article-title":"Molecular mechanisms of membrane targeting antibiotics","volume":"1858","author":"Epand","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"issue":"14","key":"10.1016\/j.ejmech.2018.06.023_bib21","doi-asserted-by":"crossref","first-page":"8288","DOI":"10.1039\/C6RA28443D","article-title":"Hydroxybenzylidene-indolinones, c-di-AMP synthase inhibitors, have antibacterial and anti-biofilm activities and also re-sensitize resistant bacteria to methicillin and vancomycin","volume":"7","author":"Opoku-Temeng","year":"2017","journal-title":"RSC Adv."},{"issue":"2","key":"10.1016\/j.ejmech.2018.06.023_bib22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1517\/13543780903505092","article-title":"Newer antibacterial drugs for a new century","volume":"19","author":"Devasahayam","year":"2010","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"5","key":"10.1016\/j.ejmech.2018.06.023_bib23","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMp0804651","article-title":"Antibiotic-resistant bugs in the 21st century\u2013a clinical super-challenge","volume":"360","author":"Arias","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2018.06.023_bib24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1021\/acsmedchemlett.6b00296","article-title":"1,2,4-Triazolidine-3-thiones as narrow spectrum antibiotics against multidrug-resistant Acinetobacter baumannii","volume":"8","author":"Huggins","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"issue":"45","key":"10.1016\/j.ejmech.2018.06.023_bib25","doi-asserted-by":"crossref","first-page":"11254","DOI":"10.1002\/anie.201206911","article-title":"Potent small-molecule suppression of oxacillin resistance in methicillin-resistant Staphylococcus aureus","volume":"51","author":"Harris","year":"2012","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"9","key":"10.1016\/j.ejmech.2018.06.023_bib26","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1021\/acs.jmedchem.6b01834","article-title":"Discovery and optimization of isoquinoline ethyl ureas as antibacterial agents","volume":"60","author":"Panchaud","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"issue":"31","key":"10.1016\/j.ejmech.2018.06.023_bib27","doi-asserted-by":"crossref","first-page":"6548","DOI":"10.1039\/C7OB01429E","article-title":"Drug design based on pentaerythritol tetranitrate reductase: synthesis and antibacterial activity of Pogostone derivatives","volume":"15","author":"Wang","year":"2017","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2018.06.023_bib28","series-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Ninth Edition: Approved Standard M07-A9. Wayne, PA","author":"CLSI","year":"2012"},{"issue":"8","key":"10.1016\/j.ejmech.2018.06.023_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182821","article-title":"Bacteriological profiling of diphenylureas as a novel class of antibiotics against methicillin-resistant Staphylococcus aureus","volume":"12","author":"Mohammad","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ejmech.2018.06.023_bib30","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1128\/AAC.01285-10","article-title":"Investigation of the potential for mutational resistance to XF-73, retapamulin, mupirocin, fusidic acid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus isolates during a 55-passage study","volume":"55","author":"Farrell","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.ejmech.2018.06.023_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142321","article-title":"Antibacterial evaluation of synthetic thiazole compounds in\u00a0vitro and in\u00a0vivo in a methicillin-resistant Staphylococcus aureus (MRSA) skin infection mouse model","volume":"10","author":"Mohammad","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ejmech.2018.06.023_bib32","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1093\/cid\/cit178","article-title":"Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections?","volume":"56","author":"van Hal","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.ejmech.2018.06.023_bib33","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/jac\/42.6.721","article-title":"The in-vitro activity of linezolid (U-100766) and tentative breakpoints","volume":"42","author":"Wise","year":"1998","journal-title":"J.\u00a0Antimicrob. Chemother."},{"issue":"Suppl 2","key":"10.1016\/j.ejmech.2018.06.023_bib34","first-page":"ii17","article-title":"Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections","volume":"51","author":"MacGowan","year":"2003","journal-title":"J.\u00a0Antimicrob. Chemother."},{"issue":"8","key":"10.1016\/j.ejmech.2018.06.023_bib35","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nrmicro1464","article-title":"Multidrug-resistance efflux pumps - not just for resistance","volume":"4","author":"Piddock","year":"2006","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2018.06.023_bib36","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3389\/fmicb.2015.00421","article-title":"Recent advances toward a molecular mechanism of efflux pump inhibition","volume":"6","author":"Opperman","year":"2015","journal-title":"Front. Microbiol."},{"issue":"5","key":"10.1016\/j.ejmech.2018.06.023_bib37","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1128\/AAC.05985-11","article-title":"No decrease in susceptibility to NVC-422 in multiple-passage studies with methicillin-resistant Staphylococcus aureus, S. aureus, Pseudomonas aeruginosa, and Escherichia coli","volume":"56","author":"D'Lima","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.06.023_bib38","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2147\/DDDT.S72129","article-title":"Efficacy of short novel antimicrobial and anti-inflammatory peptides in a mouse model of methicillin-resistant Staphylococcus aureus (MRSA) skin infection","volume":"8","author":"Mohamed","year":"2014","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2018.06.023_bib39","doi-asserted-by":"crossref","first-page":"16407","DOI":"10.1038\/srep16407","article-title":"Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent","volume":"5","author":"Thangamani","year":"2015","journal-title":"Sci. Rep."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418305142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418305142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T14:43:13Z","timestamp":1568904193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418305142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":39,"alternative-id":["S0223523418305142"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.06.023","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N-(1,3,4-oxadiazol-2-yl)benzamide analogs, bacteriostatic agents against methicillin- and vancomycin-resistant bacteria","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}